Study of eptinezumab in people with frequent migraine
Treatments studied
Part of Brain & nervous system clinical trials.
This real-world study looks at how well eptinezumab (an antibody medicine for migraine prevention) works for people with frequent episodic or chronic migraine as they get usual care. You may be asked to share health information and treatment details to see what helps most in everyday life.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 18 and 75 years old
- You have frequent migraine: either high-frequency episodic migraine (at least 8 disabling migraine days per month in the last 3 months) or chronic migraine
- You are willing to sign the informed consent form
- Your headaches are migraine (not another type of headache disorder)
- You have not had an allergic reaction or bad intolerance to eptinezumab or its ingredients
- You are not currently taking another “mAb” antibody medicine for treatment
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests if eptinezumab can stop a migraine attack that is already happening. It may help people who get migraines often and are already part of the TACHIS study.
This study tests an add-on migraine medicine (eptinezumab) given in the emergency room to quickly relieve a migraine attack, in addition to the usual care. It aims to see if this approach reduces pain and prevents the migraine from coming back.
This Phase 3 study tests eptinezumab to reduce migraine attacks in children who have episodic migraine (not daily chronic migraine). It may help by lowering the number of headache days and migraine days over time. You must complete a headache diary during screening to be considered.
This trial tests eptinezumab, a preventive medicine, to reduce headache frequency in teens with chronic migraine. It may help your teen if they have frequent migraine days despite usual care.
This trial studies eptinezumab, a migraine treatment, in children and teens ages 6 to 17 who already completed an earlier migraine study. It mainly helps doctors learn whether the treatment can be continued safely and effectively over time.
This study tracks how well new migraine medications (like Aimovig, Emgality, Ajovy, Vyepti, Qulipta, and Nurtec) work in everyday use. It may help you and your doctor understand if these treatments are a good option for your migraines.
Hear when a new Migraine Disorders trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.